Crohn'
Conditions
Interventions
Administration of pancrelipase
Sponsors
Department of Gastroenterology Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)The patient who has agreed with participation of this research with the consent explanatory note document 2)An adult IBD patient aged 20 and over 3)The patient who continued the existing medical treatment including an anti-TNF-alpha antibody two months or more 4)A patient with the water or a muddy stool, or a less than 20-BMI patient 5)A patient with a low disease activity endoscopically.
Exclusion criteria
Exclusion criteria: 1) The patient who has merged chronic pancreatitis 2) A patient with the past of the stomach and pancreatectomy 3) The patient who has allergy in pig protein 4) A patient under a pregnant woman and breast-feeding and with a possibility of having become pregnant 5) The patient who has participated in other clinical trials 6) The patient who has suffered from critical infection. 7) The patient who was not able to get consent to the participation in this clinical study. In addition, the patient whom the examination responsibility (assignment) doctor judged to be unsuitable as a subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Does the increase group in BMI 5% after 24 weeks of medication exceed a threshold value effectiveness rate from before medication or not? | — |
Countries
Japan
Contacts
Public ContactNoriko Kamata
Osaka City University Graduate School of Medicine Department of Gastroenterology
Outcome results
None listed